TNXP

Company Overview — What Does Tonix Pharmaceuticals Holding Corp. Do?

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey. Tonix Pharmaceuticals Holding Corp. (TNXP) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Seth Lederman and employs approximately 50 people, headquartered in NEW YORK, New Jersey. With a market capitalization of $194M, TNXP is one of the notable companies in the Healthcare sector.

Tonix Pharmaceuticals Holding Corp. (TNXP) Stock Rating — Avoid (April 2026)

As of April 2026, Tonix Pharmaceuticals Holding Corp. receives a Avoid rating with a composite score of 20.7/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.TNXP ranks #4,027 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Tonix Pharmaceuticals Holding Corp. ranks #700 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

TNXP Stock Price and 52-Week Range

Tonix Pharmaceuticals Holding Corp. (TNXP) currently trades at $12.60. The stock lost $0.40 (3.1%) in the most recent trading session. The 52-week high for TNXP is $69.97, which means the stock is currently trading -82.0% from its annual peak. The 52-week low is $13.07, putting the stock -3.6% above its annual trough. Recent trading volume was 316K shares, suggesting relatively thin trading activity.

Is TNXP Overvalued or Undervalued? — Valuation Analysis

Tonix Pharmaceuticals Holding Corp. (TNXP) carries a value factor score of 12/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.76x, versus the sector average of 2.75x. The price-to-sales ratio is 17.62x, compared to 1.66x for the average Healthcare stock.

At current multiples, Tonix Pharmaceuticals Holding Corp. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Tonix Pharmaceuticals Holding Corp. Profitability — ROE, Margins, and Quality Score

Tonix Pharmaceuticals Holding Corp. (TNXP) earns a quality factor score of 18/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -37.3%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -33.0% versus the sector average of -33.1%.

On a margin basis, Tonix Pharmaceuticals Holding Corp. reports gross margins of 25.2%, compared to 71.5% for the sector. The operating margin is -908.4% (sector: -66.1%). Net profit margin stands at -896.1%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 49.0% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

TNXP Debt, Balance Sheet, and Financial Health

Tonix Pharmaceuticals Holding Corp. has a debt-to-equity ratio of 13.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 7.42x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $190M.

TNXP has a beta of 1.39, meaning it is more volatile than the broader market — a $10,000 investment in TNXP would be expected to move 39.0% more than the S&P 500 on any given day. The stability factor score for Tonix Pharmaceuticals Holding Corp. is 18/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Tonix Pharmaceuticals Holding Corp. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Tonix Pharmaceuticals Holding Corp. reported revenue of $11M and earnings per share (EPS) of $-14.57. Net income for the quarter was $-91M. Gross margin was 25.2%. Operating income came in at $-93M.

In FY 2025, Tonix Pharmaceuticals Holding Corp. reported revenue of $13M and earnings per share (EPS) of $-14.57. Net income for the quarter was $-124M. Gross margin was 49.3%. Revenue grew 29.8% year-over-year compared to FY 2024. Operating income came in at $-126M.

In Q3 2025, Tonix Pharmaceuticals Holding Corp. reported revenue of $3M and earnings per share (EPS) of $-3.59. Net income for the quarter was $-32M. Gross margin was 58.5%. Revenue grew 16.6% year-over-year compared to Q3 2024. Operating income came in at $-33M.

In Q2 2025, Tonix Pharmaceuticals Holding Corp. reported revenue of $2M and earnings per share (EPS) of $-3.86. Net income for the quarter was $-28M. Gross margin was -63.8%. Revenue grew -9.5% year-over-year compared to Q2 2024. Operating income came in at $-28M.

Over the past 8 quarters, Tonix Pharmaceuticals Holding Corp. has demonstrated a growth trajectory, with revenue expanding from $2M to $11M. Investors analyzing TNXP stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

TNXP Dividend Yield and Income Analysis

Tonix Pharmaceuticals Holding Corp. (TNXP) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

TNXP Momentum and Technical Analysis Profile

Tonix Pharmaceuticals Holding Corp. (TNXP) has a momentum factor score of 18/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 23/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 50/100 reflects moderate short selling activity.

TNXP vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Tonix Pharmaceuticals Holding Corp. (TNXP) ranks #700 out of 838 stocks based on the Blank Capital composite score. This places TNXP in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing TNXP against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full TNXP vs S&P 500 (SPY) comparison to assess how Tonix Pharmaceuticals Holding Corp. stacks up against the broader market across all factor dimensions.

TNXP Next Earnings Date

No upcoming earnings date has been announced for Tonix Pharmaceuticals Holding Corp. (TNXP) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy TNXP? — Investment Thesis Summary

The quantitative profile for Tonix Pharmaceuticals Holding Corp. suggests caution. The quality score of 18/100 flags below-average profitability. The value score of 12/100 indicates premium valuation. Momentum is weak at 18/100, a headwind for near-term performance. High volatility (stability score 18/100) increases portfolio risk.

In summary, Tonix Pharmaceuticals Holding Corp. (TNXP) earns a Avoid rating with a composite score of 20.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on TNXP stock.

Related Resources for TNXP Investors

Explore more research and tools: TNXP vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare TNXP head-to-head with peers: TNXP vs AZN, TNXP vs SLGL, TNXP vs VMD.